Phase II study of weekly docetaxel and trastuzumab for patients with HER-2–overexpressing metastatic breast cancer
…, D Booser, LT Guerra, JL Murray, L Pusztai… - Journal of Clinical …, 2002 - ascopubs.org
PURPOSE: To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in
women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with …
women with HER-2–overexpressing metastatic breast cancer. Efficacy was correlated with …
Smoking and causes of death among US veterans: 16 years of observation
E Rogot, JL Murray - Public health reports, 1980 - ncbi.nlm.nih.gov
… Murray is an epidemiologist, Biometry Branch, National Cancer Institute. Tearsheet
requests to Mr. Rogot. … L.:Epidemiologic studies of Parkinson's disease. Am J Epidemiol …
requests to Mr. Rogot. … L.:Epidemiologic studies of Parkinson's disease. Am J Epidemiol …
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial
…, NL Bartlett, RJ Schilder, JL Murray… - Blood, The Journal …, 2002 - ashpublications.org
Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma
(NHL) have an increased risk of chemotherapy-induced myelosuppression following …
(NHL) have an increased risk of chemotherapy-induced myelosuppression following …
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin's lymphoma
…, GA Wiseman, C Emmanouilides, JL Murray… - Journal of Clinical …, 2003 - ascopubs.org
Purpose: Radioimmunotherapy (RIT) with yttrium-90 ( 90 Y)-labeled anti-CD20 antibody ( 90
Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a …
Y ibritumomab tiuxetan; Zevalin, IDEC Pharmaceuticals Corporation, San Diego, CA) has a …
[PDF][PDF] Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
T Iwamoto, D Booser, V Valero, JL Murray, K Koenig… - J Clin Oncol, 2012 - academia.edu
Purpose We examined borderline estrogen receptor (ER)–positive cancers, defined as having
1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the …
1% to 10% positivity by immunohistochemistry (IHC), to determine whether they show the …
Rab 5 is required for the cellular entry of dengue and West Nile viruses
The mechanisms of cellular entry of dengue and West Nile viruses are not well characterized.
We show that both these viruses enter HeLa cells by clathrin-dependent endocytosis and …
We show that both these viruses enter HeLa cells by clathrin-dependent endocytosis and …
Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in …
…, M Chavez-MacGregor, NK Ibrahim, JL Murray… - JAMA …, 2017 - jamanetwork.com
Importance Triple-negative breast cancer (TNBC) classified by transcriptional profiling as
the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (…
the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (…
Cationic Liposome-Mediated E1A Gene Transfer to Human Breast and Ovarian Cancer Cells and Its Biologic Effects: A Phase I Clinical Trial
…, P Anklesaria, NK Ibrahim, JL Murray… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: Preclinical studies have demonstrated that the adenovirus type 5 E1A gene is
associated with antitumor activities by transcriptional repression of HER-2/neu and induction …
associated with antitumor activities by transcriptional repression of HER-2/neu and induction …
Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine
…, MT Hueman, EA Mittendorf, JL Murray… - Journal of Clinical …, 2008 - ascopubs.org
Purpose HER-2/neu is overexpressed in breast cancer and is the source of immunogenic
peptides. CD4 + T-helper peptides for HER-2/neu are being evaluated in vaccine trials. The …
peptides. CD4 + T-helper peptides for HER-2/neu are being evaluated in vaccine trials. The …
Rab9 GTPase is required for replication of human immunodeficiency virus type 1, filoviruses, and measles virus
JL Murray, M Mavrakis, NJ McDonald, M Yilla… - Journal of …, 2005 - Am Soc Microbiol
Rab proteins and their effectors facilitate vesicular transport by tethering donor vesicles to
their respective target membranes. By using gene trap insertional mutagenesis, we identified …
their respective target membranes. By using gene trap insertional mutagenesis, we identified …